Tootfinder

Eli Lilly to acquire psychedelics drugmaker for $2.8B
Eli Lilly announced on Thursday that it's buying psychedelic drugmaker AtaiBeckley for $2.8 billion, expanding into experimental treatments for severe mental illness prioritized by a recent White House executive order. AtaiBeckley is developing a series of drugs based on the hallucinogen DMT, as well as on MDMA, which is more commonly known as ecstasy.